- Investing Ideas
- /
- Hong Kong Biotech Breakthroughs
Hong Kong Biotech Breakthroughs
Results
10
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
10 companies
CARsgen Therapeutics Holdings
Market Cap: HK$8.6b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$15.65
7D
-2.6%
1Y
43.1%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$103.2b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$429.40
7D
-7.9%
1Y
168.9%
Akeso
Market Cap: HK$108.3b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$114.00
7D
-7.6%
1Y
82.1%
Cutia Therapeutics
Market Cap: HK$1.8b
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$4.74
7D
-3.3%
1Y
13.9%
Qyuns Therapeutics
Market Cap: HK$4.9b
A clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in the People’s Republic of China.
2509
HK$22.48
7D
-2.0%
1Y
225.8%
Everest Medicines
Market Cap: HK$13.5b
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
1952
HK$37.74
7D
-5.1%
1Y
-4.6%
InnoCare Pharma
Market Cap: HK$23.8b
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.
9969
HK$12.20
7D
-6.7%
1Y
112.5%
CStone Pharmaceuticals
Market Cap: HK$8.1b
A biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally.
2616
HK$5.46
7D
-12.9%
1Y
123.8%
CanSino Biologics
Market Cap: HK$13.2b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$35.70
7D
-7.9%
1Y
26.6%
Mirxes Holding
Market Cap: HK$11.6b
A micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China.
2629
HK$43.36
7D
4.6%
1Y
n/a